Results 261 to 270 of about 625,224 (357)

Novel Para-Phenylenediamine-Based Derivatives as Receptor Tyrosine Kinase-like Orphan Receptor 1 (ROR1) Inhibitors: An In Vitro Preliminary Characterization. [PDF]

ChemMedChem
Smaldone G, Miranda MR, Di Matteo F, Napolitano V, Aliberti M, Musella S, Di Sarno V, Lauro G, Bifulco G, Pepe G, Aquino G, Tecce MF, Gomez-Monterrey IM, Campiglia P, Ostacolo C, Bertamino A, Vestuto V, Ciaglia T.   +17 more
europepmc   +1 more source

eLife Assessment: ACK1 and BRK non-receptor tyrosine kinase deficiencies are associated with familial systemic lupus and involved in efferocytosis [PDF]

Tomohiro Kurosaki
openalex   +1 more source

Synthetic Lethal Therapy Based on Dimorphism for Systemic Infection of Drug‐Resistant Candida albicans

Advanced Science, EarlyView.
To tackle the alarming mortality rate linked to Candida albicans infections, a synthetic lethal strategy precisely aimed at the two distinct forms of this fungus: yeast and hyphae is formulated. Ultimately, through the innovative use of macrophage membranes for drug delivery, the effectiveness of this strategy is substantially boosted while ...
Yang Gao, Jiahe Su, Jiawei Yuan, Qinyan Cao, Yue Wu, Yuyang Xiao, Guang Yang, Ruomu Xia, Jingpeng Yang, Yanan Li, Lina Wu, He Huang, Lingtong Meng   +12 more
wiley   +1 more source

The expanding role of the receptor tyrosine kinase MET as a therapeutic target in non-small cell lung cancer. [PDF]

Cell Rep Med
Sattler M, Salgia R.
europepmc   +1 more source

Dynamic Decoration of DNA Scaffolds for High‐Resolution Cancer Cell Subtyping

Advanced Science, EarlyView.
This study presents a dual‐mode imaging platform that utilizes self‐assembly and disassembly of DNA scaffolds for high‐resolution cancer cell detection. The structural rigidity of DNA scaffolds effectively prevents cellular internalization for over 300 min.
Xiaolin Hu, Jie Xie, Xinlin Guo, Liangting Wang, Zhengheng Yu, Xiaopei Qiu, Heng Li, Kang Wang, Xiaoxing Wang, Mingxuan Song, Junsong Guo, Wei Gu, Sergio Bernardini, Chaoyong Yang, Hong Zhang, Yang Luo   +15 more
wiley   +1 more source

SIRT5–RAC2 Axis Drives Monocyte‐to‐Macrophage Differentiation to Promote Inflammatory Injury in Premature Ovarian Insufficiency

Advanced Science, EarlyView.
SIRT5 desuccinylates and stabilizes RAC2, activating CSF1R‐dependent signaling to drive monocyte differentiation into M0 macrophages and their polarization toward pro‐inflammatory M1 phenotypes in CTX‐induced premature ovarian insufficiency. Inhibiting the SIRT5‐RAC2 axis attenuates inflammation, reduces granulosa cell apoptosis, and preserves ...
Wenjing TanTai, Yaqi Li, Shengnan Liu, Minjuan Wu, Zhixiao Liu, Junfeng Jiang, Jingjing Chen, Xiaoding Xu, Li Li, Chaoqun Li, Fang Zhao, Ye Liu, Haitao Ni, Tengfei Zhang, Mingjuan Xu, Chaofeng Han   +15 more
wiley   +1 more source

Resistance patterns of non-small cell lung cancer treated with third-generation epidermal growth factor receptor-tyrosine kinase inhibitors. [PDF]

Am J Cancer Res
Chen N, Zhao F, Yang L, Tan X, Wang D, Ye X, Wei Z.   +6 more
europepmc   +1 more source

Universal Antibody‐Engineered Lipid Nanoparticles Potentiate Chemo‐Immunotherapy Against Triple‐Negative Breast Cancer by Reprogramming Tumor Cell Metabolism

Advanced Science, EarlyView.
A universal ROR1 antibody‐engineered lipid nanoparticle (LNP) is constructed by sequential drug encapsulation and antibody conjugation. The LNP not only enables enhanced chemotherapeutic efficiency by targeting drug delivery and precise localization of deep‐seated tumors through NIR‐II fluorescence imaging, but also remodels immunosuppressive TME ...
Yeneng Dai, Jiaqi Wang, Yu Liu, Guanda Jiao, Yuheng Gu, Yang Liu, Shengyu Fu, Xing Fan, Jialin Li, Ziang Guo, Kam Tong Leung, Lipeng Zhu, Qi Zhao   +12 more
wiley   +1 more source

Correction: Small molecule inhibition of Axl receptor tyrosine kinase potently suppresses multiple malignant properties of glioma cells. [PDF]

Oncotarget
Vouri M, An Q, Birt M, Pilkington GJ, Hafizi S.   +4 more
europepmc   +1 more source

Cytokine‐Engineered Chimeric Antigen Receptor‐T Cell Therapy: How to Balance the Efficacy and Toxicity

Advanced Science, EarlyView.
Cytokine‐engineered CAR‐T cells represent a promising immunotherapy against malignancies due to direct tumor killing and potent immunity response. However, significant toxicities, including CRS and ICANS, have restricted clinical applications. How to keep the risk‐benefit balance of the advanced therapy is of great importance for maximizing the benefit
Xinru Zhang, Gulizeba Aimaiti, Yuanye Guan, Yuzhe Sha, Wei Zhou, Jiefeng Shen, Bo Zhao, Wei‐En Yuan   +7 more
wiley   +1 more source